Evidence map›Paper›PMID 40142602›Full record

ArticleJournal of clinical medicine2025

Relapse Rates and Predictors for Relapse in Ulcerative Colitis and Crohn's Disease Patients After Discontinuation of Vedolizumab or Ustekinumab: The REVEUS Study.

Alessandro Massano, Edoardo Vincenzo Savarino, Simone Saibeni, Cristina Bezzio, Lorenzo Bertani, Gian Paolo Caviglia, Marta Vernero, Angelo Armandi, Davide Giuseppe Ribaldone

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Alessandro MassanoGastroenterology Unit, Department of Surgery, Oncology and Gastroenterology, Azienda Ospedale Università Padova, University of Padua, 35121 Padova, Italy.ORCID 0000-0002-9064-3434
Edoardo Vincenzo SavarinoGastroenterology Unit, Department of Surgery, Oncology and Gastroenterology, Azienda Ospedale Università Padova, University of Padua, 35121 Padova, Italy.ORCID 0000-0002-3187-2894
Simone SaibeniIBD Centre, Gastroenterology Unit, Rho Hospital, ASST Rhodense, 20017 Rho, Italy.ORCID 0000-0001-5677-2534
Cristina BezzioIBD Centre, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy.
Lorenzo BertaniAzienda Ospedaliera Universitaria Pisana, 56126 Pisa, Italy.ORCID 0000-0001-8653-1790
Gian Paolo CavigliaDepartment of Medical Sciences, University of Turin, 10126 Turin, Italy.ORCID 0000-0002-0529-9481
Marta VerneroDepartment of Medical Sciences, University of Turin, 10126 Turin, Italy.
Angelo ArmandiDepartment of Medical Sciences, University of Turin, 10126 Turin, Italy.ORCID 0000-0002-7245-4445
Davide Giuseppe RibaldoneDepartment of Medical Sciences, University of Turin, 10126 Turin, Italy.ORCID 0000-0002-9421-3087

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

advanced therapyanti-IL12/23anti-integrinbiologicsdiscontinuationpredictorsrelapseretreatmenttarget therapywithdrawal

Identifiers

PMID40142602
PMCPMC11943183

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.